Comparative Pharmacology
Head-to-head clinical analysis: EVISTA versus TOREMIFENE CITRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVISTA versus TOREMIFENE CITRATE.
EVISTA vs TOREMIFENE CITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective estrogen receptor modulator (SERM) that binds to estrogen receptors, acting as an agonist in bone and antagonist in breast and uterine tissues.
Nonsteroidal estrogen receptor antagonist; binds to estrogen receptors (ER) with high affinity, competitively inhibiting estrogen binding and exerting antiestrogenic effects. Also possesses weak estrogenic agonist activity.
60 mg orally once daily.
60 mg orally once daily
None Documented
None Documented
Terminal elimination half-life is approximately 32.5 hours (range 27-39 hours) for raloxifene and its glucuronide conjugates; clinically relevant for once-daily dosing.
About 5 days for the parent compound; clinical context: steady-state achieved in ~4 weeks
Raloxifene undergoes extensive glucuronidation; <0.1% excreted unchanged in urine. Approximately 95% is excreted in feces over 5 days (primarily as glucuronide conjugates). Renal elimination of unchanged drug is negligible (<0.1%).
Primarily fecal (biliary excretion) as metabolites; approximately 10% renal
Category C
Category C
Selective Estrogen Receptor Modulator
Selective Estrogen Receptor Modulator